Piramal Critical Care and BREPCO Gain MHRA Approval for NeoAtrico in the UK

Piramal Critical Care, a business unit of Piramal Pharma Limited, and BREPCO have revealed that their innovative product, NeoAtrico, has obtained marketing consent from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA). This is a major achievement towards establishing Piramal's presence in critical care solutions.

 

Important points:

Piramal Critical Care has cutting-edge manufacturing units in India and the US with high-quality production standards. MHRA approval will help to make innovative therapies more accessible to UK patients and solidify Piramal's position as a global leader in hospital generics and critical care solutions.

 

Sources: Piramal Pharma Regulatory Filing, GOV.UK Marketing Authorizations Update, March 20, 2025